Chinese Medical Sciences Journal ›› 2018, Vol. 33 ›› Issue (2): 120-126.doi: 10.24920/21805
收稿日期:
2017-08-08
出版日期:
2018-06-30
发布日期:
2018-06-13
通讯作者:
陈跃鑫
E-mail:cyuexin@163.com
Zhou Mengxin,Sun Rui,Chen Yuexin()
Received:
2017-08-08
Published:
2018-06-30
Online:
2018-06-13
Contact:
Chen Yuexin
E-mail:cyuexin@163.com
摘要:
合并静脉血栓栓塞症(VTE)和冠心病(CHD)的患者在临床上并不少见。治疗这类患者的主要挑战是针对VTE和CHD的抗栓治疗原则不尽相同,如果联合用药则增加出血风险。因此应根据患者疾病情况评估疗效和出血风险,以选用最佳抗栓治疗方案。本文讨论了同时合并VTE和CHD的患者在不同情况下,如何根据病情和出血风险,选择相应的抗栓治疗,包括联合抗凝药物治疗、双联抗血小板治疗、三联抗栓治疗、溶栓治疗及后续长期治疗,以期为这类患者制定规范的、安全而有效的治疗方案提供参考。同时,本文还就新型口服抗凝药的应用及出血风险的评估方法进行了展望。
Zhou Mengxin, Sun Rui, Chen Yuexin. A Literature Review of Antithrombotic Therapy for Patients of Venous Thromboembolic Events with Comorbidity of Coronary Heart Disease[J].Chinese Medical Sciences Journal, 2018, 33(2): 120-126.
1. |
Cheuk BL, Cheung GC, Cheng SW . Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 2004; 91(4):424-8. doi: 10.1002/bjs.4454.
doi: 10.1002/bjs.4454 |
2. |
Heit JA, Spencer FA, White RH . The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41(1):3-14. doi: 10.1007/s11239-015-1311-6.
doi: 10.1007/s11239-015-1311-6 |
3. |
Liao S, Woulfe T, Hyder S , et al. Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study. J Thromb Haemost 2014; 12(2):214-9. doi: 10.1111/jth.12464.
doi: 10.1111/jth.12464 pmid: 24283769 |
4. |
Sanchis-Gomar F, Perez-Quilis C, Leischik R , et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016; 4(13):256. doi: 10.21037/atm.2016.06.33.
doi: 10.21037/atm.2016.06.33 pmid: 27500157 |
5. |
Sui H, Chen WW , Wang W. Interpretation of report on cardiovascular diseases in China ( 2015). Chin J Cardiovasc Med 2016; 21(4): 259-61. Chinese. doi: 10.3969/j.issn.1007-5410.2016.04.001.
doi: 10.3969/j.issn.1007-5410.2016.04.001 |
6. |
Fang BM. Emphasizing the diagnosis and treatment of pulmonary thromboembolism concurrent with coronary heart disease. Chin J Cardiovasc Med 2008; 18(3): 167-70. Chinese. doi: 10.3969/j.issn.1007-5410.2008.03.003.
doi: 10.3969/j.issn.1007-5410.2008.03.003 |
7. |
Zhang XF, Zhu GF, Liu S. Clinical characteristics and intervention of pulmonary thromboembolism patients with coronary atherosclerotic heart disease. Chin General Practice 2011; 14(31): 3577-9. Chinese. doi: 10.3969/j.issn.1007-9572.2011.31.013.
doi: 10.3969/j.issn.1007-9572.2011.31.013 |
8. |
Braekkan SK, Mathiesen EB, Njølstad I , et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Troms? study. J Thromb Haemost 2008; 6(11):1851-7. doi: 10.1111/j.1538-7836.2008.03102.x.
doi: 10.1111/j.1538-7836.2008.03102.x pmid: 18665924 |
9. |
Bruzelius M, Strawbridge RJ, Trégouët DA , et al. Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism. Thromb Res 2014; 134(2):426-32. doi: 10.1016/j.thromres.2014.03.054.
doi: 10.1016/j.thromres.2014.03.054 pmid: 24745723 |
10. |
Franchini M, Mannucci PM . Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med 2008; 19(7):476-81. doi: 10.1016/j.ejim.2007.10.019.
doi: 10.1016/j.ejim.2007.10.019 pmid: 19013373 |
11. |
Mi Y, Yan S, Lu Y , et al. Venous thromboembolism has the same risk factors as atherosclerosis: A Prisma compliant systemic review and meta-analysis. Medicine (Baltimore) 2016; 95(32):e4495. doi: 10.1097/MD.0000000000004495.
doi: 10.1097/MD.0000000000004495 |
12. |
Lijfering WM, Flinterman LE, Vandenbroucke JP , et al. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 2011; 37(8):885-96. doi: 10.1055/s-0031-1297367.
doi: 10.1055/s-0031-1297367 |
13. |
Sørensen HT, Horvath-Puho E, Søgaard KK , et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7(4):521-8. doi: 10.1111/j.1538-7836.2009.03279.x.
doi: 10.1111/j.1538-7836.2009.03279.x pmid: 19192118 |
14. |
Sørensen HT, Horvath-Puho E, Pedersen L , et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370(9601):1773-9. doi: 10.1016/S0140-6736(07)61745-0.
doi: 10.1016/S0140-6736(07)61745-0 |
15. |
Committee of Experts on Rational Drug Use of the National Health and Family Planning Commission of the PRC, Chinese Pharmacists Association. Guideline of rational drug therapy for the Coronary heart disease. Chin J Fronti Med Sci 2016( 06): 19-108. Chinese. doi: 10.3969/j.issn.1674-7372.2016.06.007.
doi: 10.3969/j.issn.1674-7372.2016.06.007 |
16. |
Xiong CM , Hu EC. Strategy of diagnosis and treatment in the coronary heart disease that concurrent with pulmonary thromboembolism. Chin J Clinicians 2013; 7(15): 6788-91. Chinese. doi: 10.3969/cma.j.issn.1674-0785.2013.15.002.
doi: 10.3969/cma.j.issn.1674-0785.2013.15.002 |
17. |
Konstantinides SV, Torbicki A, Agnelli G , et al. Task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35(43): 3033- 69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283.
doi: 10.1093/eurheartj/ehu283 |
18. |
Castellucci LA, Cameron C, Le Gal G , et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 2014; 312(11):1122-35. doi: 10.1001/jama.2014.10538.
doi: 10.1001/jama.2014.10538 |
19. |
van der Hulle T, Kooiman J, den Exter PL , et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12(3):320-8. doi: 10.1111/jth.12485.
doi: 10.1111/jth.12485 |
20. |
Ageno W, Gallus AS, Wittkowsky A , et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292.
doi: 10.1378/chest.11-2292 |
21. |
Verdecchia P, Angeli F, Aita A , et al. Why switch from warfarin to NOACs? Intern Emerg Med 2016; 11(3):289-93. doi: 10.1007/s11739-016-1411-0.
doi: 10.1007/s11739-016-1411-0 pmid: 26972708 |
22. |
Prandoni P, Milan M, Barbar S , et al. Incidence of arterial embolism in patients on treatment with old and new anticoagulants for venous thromboembolism. Semin Thromb Hemost 2015; 41(2):154-9. doi: 10.1055/s-0035-1544162.
doi: 10.1055/s-0035-1544162 pmid: 25703245 |
23. |
Rohla M, Weiss TW, Wojta J , et al. Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. Eur Heart J Cardiovasc Pharmacother 2015; 1(3):191-7. doi: 10.1093/ehjcvp/pvv014.
doi: 10.1093/ehjcvp/pvv014 pmid: 27533995 |
24. |
Asencio LA, Huang JJ, Alpert JS . Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? Am J Med 2014; 127(7):579-85. doi: 10.1016/j.amjmed.2014.02.030.
doi: 10.1016/j.amjmed.2014.02.030 pmid: 24608021 |
25. |
Paikin JS, Wright DS, Eikelboom JW . Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Rev 2011; 25(3):123-9. doi: 10.1016/j.blre.2011.01.007.
doi: 10.1016/j.blre.2011.01.007 pmid: 21354678 |
26. |
Sanchez O, Planquette B, Meyer G . Management of massive and submassive pulmonary embolism: focus on recent randomized trials. Curr Opin Pulm Med 2014; 20(5):393-9. doi: 10.1097/MCP.0000000000000089.
doi: 10.1097/MCP.0000000000000089 pmid: 3542486 |
27. |
Wang C, Zhai Z, Yang Y , et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; 137(2):254-62. doi: 10.1378/chest.09-0765.
doi: 10.1378/chest.09-0765 |
28. |
Sharifi M, Bay C, Skrocki L , et al. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol 2013; 111(2):273-7. doi: 10.1016/j.amjcard.2012.09.027.
doi: 10.1016/j.amjcard.2012.09.027 pmid: 23102885 |
29. |
DeEugenio D, Kolman L, DeCaro M , et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007; 27(5):691-6. doi: 10.1592/phco.27.5.691.
doi: 10.1592/phco.27.5.691 pmid: 17461704 |
30. | Saheb KJ, Deng BQ, Hu QS , et al. Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis. Chin Med J 2013; 126(13):2536-42. |
31. | Khurram Z, Chou E, Minutello R , et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18(4):162-4. |
32. |
Rubboli A, Milandri M, Castelvetri C , et al. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 2005; 104(2):101-6. doi: 10.1159/000086918.
doi: 10.1159/000086918 |
33. |
Gibson CM, Mehran R, Bode C , et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375(25):2423-34. doi: 10.1056/NEJMoa1611594.
doi: 10.1056/NEJMoa1611594 pmid: 27959713 |
34. |
Mekaj YH, Daci FT, Mekaj AY . New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag 2015; 11:1449-56. doi: 10.2147/TCRM.S92222.
doi: 10.2147/TCRM.S92222 pmid: 4590672 |
35. |
Becattini C, Agnelli G, Schenone A , et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366(21):1959-67. doi: 10.1056/NEJMoa1114238.
doi: 10.1056/NEJMoa1114238 |
36. |
Brighton TA, Eikelboom JW, Mann K , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367(21):1979-87. doi: 10.1056/NEJMoa1210384.
doi: 10.1056/NEJMoa1210384 |
37. |
Kuijer PM, Hutten BA, Prins MH , et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159(5):457-60. doi: 10.1001/archinte.159.5.457.
doi: 10.1001/archinte.159.5.457 |
38. |
Ruíz-Giménez N, Suárez C, González R , et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100(1):26-31. doi: 10.1160/TH08-03-0193.
doi: 10.1160/TH08-03-0193 pmid: 18612534 |
39. |
Pisters R, Lane DA, Nieuwlaat R , et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5):1093-100. doi: 10.1378/chest.10-0134.
doi: 10.1378/chest.10-0134 pmid: 20299623 |
40. |
Fang MC, Go AS, Chang Y , et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58(4):395-401. doi: 10.1016/j.jacc.2011.03.031.
doi: 10.1016/j.jacc.2011.03.031 |
41. |
Gage BF, Yan Y, Milligan PE , et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151(3):713-9. doi: 10.1016/j.ahj.2005.04.017.
doi: 10.1016/j.ahj.2005.04.017 |
42. |
Kearon C, Akl EA, Ornelas J , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149(2):315-52. doi: 10.1016/j.chest.2015.11.026.
doi: 10.1016/j.chest.2015.11.026 |
43. |
Di Nisio M, Ageno W, Rutjes AW , et al. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost 2016; 115(2):424-32. doi: 10.1160/TH15-06-0474.
doi: 10.1160/TH15-06-0474 pmid: 26511068 |
44. |
Riva N, Bellesini M, Di Minno MN , et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost 2014; 112(3):511-21. doi: 10.1160/TH14-01-0081.
doi: 10.1160/TH14-01-0081 |
45. |
Klok FA, Hosel V, Clemens A , et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48(5):1369-76. doi: 10.1183/13993003. 00280-2016.
doi: 10.1183/13993003. 00280-2016 pmid: 27471209 |
46. |
Loewen P, Dahri K . Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011; 90(10):1191-200. doi: 10.1007/s00277-011-1267-3.
doi: 10.1007/s00277-011-1267-3 pmid: 00034848 |
47. |
Apostolakis S, Lane DA, Guo Y , et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60(9):861-7. doi: 10.1016/j.jacc.2012.06.019.
doi: 10.1016/j.jacc.2012.06.019 pmid: 22858389 |
48. |
Zhu W, He W, Guo L , et al. The HAS-BLED Score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015; 38(9):555-61. doi: 10.1002/clc.22435.
doi: 10.1002/clc.22435 pmid: 26418409 |
49. |
Esteve-Pastor MA, Garcia-Fernandez A, Macias M , et al. Is the ORBIT bleeding risk score superior to the HAS-BLED score in anticoagulated atrial fibrillation patients? Circ J 2016; 80(10):2102-8. doi: 10.1253/circj.CJ-16-0471.
doi: 10.1253/circj.CJ-16-0471 pmid: 27557850 |
50. |
Senoo K, Proietti M, Lane DA , et al. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med 2016; 129(6):600-7. doi: 10.1016/j.amjmed.2015.10.001.
doi: 10.1016/j.amjmed.2015.10.001 pmid: 26482233 |
51. |
Costa F, Tijssen JG, Ariotti S , et al. Incremental value of the CRUSADE, ACUITY, HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy. J Am Heart Assoc 2015; 4(12): pii: e002524. doi: 10.1161/JAHA.115.002524.
doi: 10.1161/JAHA.115.002524 |
[1] | 吴坤荣, 张恕芳, 关紫菀, 李晓黎, 李蕊, 尹影, 李妍. 亚甲基四氢叶酸还原酶基因C677T多态性与中国2型糖尿病患者冠心病风险增加相关[J]. Chinese Medical Sciences Journal, 2021, 36(2): 103-109. |
[2] | 林烨, 王祯莲, 严敏, 朱飞雨, 端烨, 孙志琴. 曲美他嗪对糖尿病合并冠心病患者的疗效:一项随机对照试验的荟萃分析[J]. Chinese Medical Sciences Journal, 2020, 35(3): 226-238. |
[3] | 黎简平, 傅永平, 常文秀, 易昌容, 刘丽华, 邢海燕. 过氧化物酶体增值物激活受体-γ2基因启动子区C-689T多态性与汉族人群冠心病的相关性[J]. Chinese Medical Sciences Journal, 2017, 32(3): 177-184. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
|
Supervised by National Health Commission of the People's Republic of China
9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China
Tel: 86-10-65105897 Fax:86-10-65133074
E-mail: cmsj@cams.cn www.cmsj.cams.cn
Copyright © 2018 Chinese Academy of Medical Sciences
All right reserved.
京公安备110402430088 京ICP备06002729号-1